此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

A Prospective Observational Cohort Study Protocol for Disease Severity Stratification and Prognosis Assessment in Patients With Pneumonia

2026年4月28日 更新者:Zhonghao Fang
This is a prospective, multicenter observational cohort study involving approximately 2,700 patients, designed to delineate the natural history of pneumonia by tracking the complete clinical course and dynamic multi-omics evolution from the acute phase to recovery; the study aims to quantify severe conversion rates and mortality by comparing baseline characteristics, pathogen distribution, and immune response trajectories between severe and non-severe groups, ultimately revealing the underlying molecular mechanisms of disease progression and optimizing clinical risk stratification strategies.

研究概览

地位

尚未招聘

研究类型

观察性的

注册 (估计的)

2700

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

  • 姓名:Liang Peng, Doctor
  • 电话号码:86-020-85959142
  • 邮箱:pl_206@126.com

学习地点

    • Guangdong
      • Guangzhou、Guangdong、中国
        • Fifth Affiliated Hospital of Guangzhou Medical University
        • 接触:
          • Liang Peng, Doctor
          • 电话号码:86-020-85959142
          • 邮箱:pl_206@126.com

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人
  • 年长者

接受健康志愿者

不

取样方法

概率样本

研究人群

Based on the reported overall hospital mortality rate of pneumonia of 0.80%1, to ensure the accuracy of the estimation of the primary outcome (overall hospital mortality rate), a two-sided significance level of α = 0.05 was set, with an allowable absolute error of δ = 0.6%. Using the single sample rate formula, the minimum sample size N ≈ 2010 cases was calculated. Considering that this study is a real-world observational cohort design and needs to meet requirements such as multi-subgroup analysis, sensitivity testing, and machine learning modeling, the final plan is to include at least 2400 patients with pneumonia. Given that severe pneumonia accounts for approximately 13.58% to 20.05% of pneumonia patients1,2, an epidemiological proportion of 15% (i.e., 1.5:8.5) was taken. It is estimated that there will be approximately 360 patients with severe pneumonia and about 2040 patients with non-severe pneumonia. Additionally, this study also included 300 hospitalized patients with suspected

描述

  1. Inclusion and Exclusion Criteria for Pneumonia Patients 1.1 Inclusion Criteria 1) Age ≥ 18 years old; 2) Meeting the diagnostic criteria for pneumonia (acute onset + new infiltrates on imaging); 3) Time from onset to admission ≤ 72 hours; 4) Signed written informed consent. 1.1.1 Inclusion Criteria for Severe Pneumonia Patients A diagnosis of "severe pneumonia" can be made if one of the main criteria or ≥ 3 of the secondary criteria are met.

    Main Criteria:

    ① Requires mechanical ventilation with tracheal intubation

    ② Requires vasopressor drugs after aggressive fluid resuscitation for septic shock

    Secondary Criteria:

    • Respiratory rate ≥ 30 breaths/min

      • PaO₂/FiO₂ ≤ 250 mm Hg

        • Multiple lobe infiltrates

          • Confusion and/or disorientation

            ⑤ Blood urea nitrogen ≥ 20 mg/dL

            ⑥ Leukopenia (WBC < 4×10⁹/L)

            ⑦ Thrombocytopenia (PLT < 100×10⁹/L)

            ⑧ Decreased body temperature (central body temperature < 36 ℃)

            ⑨ Hypotension requiring fluid resuscitation 1.2 Exclusion Criteria

            1. End-stage diseases (such as expected survival < 48 hours);
            2. Long-term immunosuppressive therapy (prednisone > 20mg/d for more than 3 weeks, or neutropenia after chemotherapy);
            3. Pregnant or lactating women. 2. Inclusion and Exclusion Criteria for Patients with Suspected Infection but Negative Pathogen Testing 2.1 Inclusion Criteria
            1. Age ≥ 18 years old;
            2. Having infection-related symptoms or signs (such as fever, cough, sputum production, elevated white blood cells, etc.), clinically suspected of pneumonia;
            3. All pathogen tests are negative within 3 days after admission;
            4. Time from onset to admission ≤ 72 hours;
            5. Signed written informed consent. 2.2 Exclusion Criteria
            1. End-stage diseases (such as expected survival < 48 hours);
            2. Long-term immunosuppressive therapy;
            3. Pregnant or lactating women;

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

队列和干预

团体/队列
肺炎
Severe pneumonia
Non-infection control group

研究衡量的是什么?

主要结果指标

结果测量
大体时间
28-day all-cause mortality
大体时间:28-day period following enrollment
28-day period following enrollment

次要结果测量

结果测量
大体时间
The incidence rate of patients in the non-severe group progressing to severe condition
大体时间:28-day period following enrollment
28-day period following enrollment
Time taken for the non-severe group to progress to the severe stage
大体时间:28-day period following enrollment
28-day period following enrollment
Duration of ICU stay
大体时间:28-day period following enrollment
28-day period following enrollment
Duration of mechanical ventilation
大体时间:28-day period following enrollment
28-day period following enrollment
Total hospitalization days
大体时间:28-day period following enrollment
28-day period following enrollment
28-day readmission rate
大体时间:28-day period following enrollment
28-day period following enrollment

其他结果措施

结果测量
大体时间
Multimodal omics analysis
大体时间:Day 0
Day 0

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

调查人员

  • 学习椅:Zifeng Yang, Doctor、The First Affiliated Hospital of Guangzhou Medical University

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年5月1日

初级完成 (估计的)

2026年5月1日

研究完成 (估计的)

2028年5月28日

研究注册日期

首次提交

2026年4月28日

首先提交符合 QC 标准的

2026年4月28日

首次发布 (实际的)

2026年5月5日

研究记录更新

最后更新发布 (实际的)

2026年5月5日

上次提交的符合 QC 标准的更新

2026年4月28日

最后验证

2026年4月1日

更多信息

与本研究相关的术语

关键字

其他研究编号

  • P-2026-001

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

IPD 计划说明

Due to concerns over patient privacy and confidentiality issues, the individual patient data (IPD) may not be shared.

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅